Faron Pharmacuetical Oy’s (LON:FARN) clinical trial of anti-cancer drug Clevegen continues to deliver encouraging results chief executive Markku Jalkanen told Proactive’s Andrew Scott.
Dosing has now reached the maximum levels with no adverse effects on patients in the study, while significant signs of increased immune activity were noted.
Nine people have now been treated and once the drug’s safety has been established, Faron will increase the number and type of patients.
Colorectal cancer will be the initial focus, but Jalkanen wants to expand into other forms of difficult to treat cancers such as liver, melanoma and pancreatic.
“Once we’ve optimised the dosing we can move into cohort escalation. The first target will be CRC but if there are strong clinical efficacy signs we can expand even further.”